skip to main content

Capecitabine Ileostomy — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGI CancersCapecitabine IleostomySCE Medical Oncology

Capecitabine monotherapy is planned at the standard 1250 mg/m² twice-daily starting schedule. Baseline Cockcroft-Gault creatinine clearance is 42 mL/min and there is no complete DPD deficiency. What initial capecitabine adjustment does the UK SmPC specify?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: EStart at seventy-five percent of the 1250 mg/m² dose and monitor closely

A Cockcroft-Gault creatinine clearance of 42 mL/min is moderate renal impairment. For a planned 1250 mg/m² capecitabine starting dose, the UK SmPC recommends a reduction to 75% with close toxicity monitoring. Full-dose 1250 mg/m² ignores the specified adjustment. A routine 50% starting dose is not specified for this renal band. The contraindication applies below 30 mL/min, not below 50. Automatic substitution with full-dose infusional fluorouracil is not the SmPC instruction and still requires an individual fluoropyrimidine assessment.

Reference: Capecitabine 500 mg UK summary of product characteristics (Current UK SmPC, accessed July 2026): https://www.medicines.org.uk/emc/product/14545/smpc